Cleveland Clinic shared a post on LinkedIn:
“New research finds the alpha-lactalbumin vaccine demonstrated an immune response in 74% of patients who presently have or are at high risk for triple-negative breast cancer.
The vaccine, targeting triple-negative breast cancer, has reached a key milestone in its clinical development.
The investigational therapy is designed to prevent recurrence in survivors by targeting a protein expressed in many TNBC tumors.
See how this approach could shift the future of breast cancer prevention and survivorship.”
Jame Abraham, Chairman and Professor at the Department of Hematology and Medical Oncology at Cleveland Clinic, shared this post, adding:
“Thank you G. Thomas Budd (Department of Hematology and Medical Onclogy) Cleveland Clinic for your pioneering work on breast cancer vaccine!”
More posts about Breast Cancer.